A highly anticipated study shows that a dual-drug combination called CagriSema helped people lose an average of 22.7% of their weight after more than a year of weekly injections, while patients receiving a placebo lost 2.3%.Novo Nordisk stated on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, falling short of its expected 25%, leading to a significant drop in its stock price.Meanwhile, competitor Eli Lilly surged over 9% in pre-market trading after Novo Nordisk released the clinical data for CagriSema, which showed that patients lost 22.7% of their weight in the trial, below previous expectations

Novo Nordisk stated on Friday that its next-generation obesity drug Cagrisema achieved only a 22.7% weight loss in a trial, below its expected 25%

- A study shows that the drug combination CagriSema led to an average weight loss of 22.7% in patients after over a year of weekly injections, compared to 2.3% in the placebo group.  
- Novo Nordisk announced that CagriSema's performance in a late-stage trial fell short of its expected 25% weight loss, resulting in a significant drop in its stock price.  
- In contrast, competitor Eli Lilly's stock rose over 9% following the release of Novo Nordisk's clinical data.

Weight loss new drug falls short of expectations, Novo Nordisk plummets nearly 30% in pre-market! Competitor Eli Lilly surges over 10%